STOCK TITAN

HALEON PLC SEC Filings

HLNCF OTC Link

Welcome to our dedicated page for HALEON PLC SEC filings (Ticker: HLNCF), a comprehensive resource for investors and traders seeking official regulatory documents including 10-K annual reports, 10-Q quarterly earnings, 8-K material events, and insider trading forms.

The HLNCF SEC filings page on Stock Titan provides access to U.S. regulatory disclosures related to Haleon plc, which files as a foreign private issuer and is listed on the London Stock Exchange and New York Stock Exchange under the symbol HLN. These filings are submitted on Form 20-F for annual reporting and Form 6-K for current reports under the Securities Exchange Act of 1934.

Haleon’s Form 6-K filings cover several important areas for investors. Some reports focus on operating model and strategy, such as the announcement of the evolution of its operating model in support of its "Win as One" strategy. These documents describe the creation of roles like Chief Growth Officer and Chief Transformation Officer, the formation of regional Operating Units, and the responsibilities of global functions.

Other 6-K filings relate to Director/PDMR Shareholding. These provide notification and public disclosure of transactions by Persons Discharging Managerial Responsibilities (PDMRs) under the UK Market Abuse Regulation, including acquisitions of partnership shares and awards of matching shares under Haleon’s Share Reward Plan, with details on the financial instruments and trading venue.

Haleon also files 6-K reports on Total Voting Rights and Capital, which set out the number of issued ordinary shares of £0.01 each, treasury shares and ordinary shares with voting rights. This information is relevant for shareholders and others with notification obligations under the UK FCA’s Disclosure Guidance and Transparency Rules.

On Stock Titan, users can review these Haleon filings in one place, with AI-powered summaries that explain the key points of each document, from strategic changes to insider transactions and share capital updates, helping to make complex regulatory text more accessible.

Rhea-AI Summary

Haleon plc reports its share capital and voting rights position as at 31 March 2026. The company has issued 8,931,093,261 ordinary shares of £0.01 each, of which 12,548,735 are held in treasury. This leaves 8,918,544,526 ordinary shares carrying voting rights, which shareholders should use as the denominator when assessing whether they must notify holdings or changes in holdings under the FCA's Disclosure Guidance and Transparency Rules.

Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
-- %
Tags
current report
-
Rhea-AI Summary

Haleon plc reports that it purchased 8,939,706 ordinary shares of £0.01 each for cancellation under its share buyback programme announced on 12 March 2026. The purchases took place between 23 and 27 March 2026 across the London Stock Exchange, CBOE (UK) and Aquis at prices between 353.7000p and 373.0000p per share.

After settlement, Haleon’s registered share capital is 8,932,831,335 ordinary shares, of which 12,548,735 are held as treasury shares. The number of ordinary shares with voting rights is now 8,920,282,600, which shareholders may use for disclosure thresholds under the FCA’s Disclosure Guidance and Transparency Rules.

Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
-- %
Tags
current report
-
Rhea-AI Summary

Haleon plc reported that Chief Executive Officer Brian McNamara received vesting of share awards on 23 March 2026 under the Haleon Performance Share Plan and the Deferred Annual Bonus Plan. The awards, which included accrued dividends, were granted over ordinary shares with a nil purchase price.

A portion of the resulting shares was automatically sold on the London Stock Exchange to cover related tax liabilities, at a price of £3.684419 per share. The Performance Share Plan award was subject to performance conditions over a period ending on 31 December 2025 and must be retained until the shareholding requirement is met, and for Executive Directors in any event for two years after receipt. The awards are also subject to malus and clawback provisions.

Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
-- %
Tags
current report
Rhea-AI Summary

Haleon plc reports that it has purchased 7,833,121 ordinary shares of £0.01 each for cancellation under its share buyback programme announced on 12 March 2026. The purchases were carried out on UK venues between 16 and 20 March 2026 at volume‑weighted average prices generally around the high‑370s to low‑390s pence per share.

After settlement of these transactions, Haleon’s registered share capital is 8,941,771,041 ordinary shares, of which 12,591,821 are held in treasury. This leaves 8,929,179,220 ordinary shares with voting rights, a figure shareholders can use for disclosure threshold calculations under the FCA’s transparency rules.

Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
-- %
Tags
current report
-
Rhea-AI Summary

Haleon plc reported recent purchases of its own shares under a previously announced buyback programme. The company bought 2,749,486 ordinary shares of £0.01 each for cancellation on 12 and 13 March 2026 across the London Stock Exchange, CBOE UK venues and Aquis.

After these transactions settle, Haleon’s registered share capital will be 8,949,604,162 ordinary shares, including 43,651,673 held in treasury. This leaves 8,905,952,489 ordinary shares with voting rights, a figure shareholders can use for regulatory disclosure thresholds.

Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
-- %
Tags
current report
-
Rhea-AI Summary

Haleon plc has published its 2025 Annual Report and Accounts & Form 20-F, together with the Notice of its 2026 Annual General Meeting. These documents are available on the company’s website and the Form 20-F is being filed with the SEC.

The 2026 AGM will be held as a virtual meeting at 3:00pm (BST) on 29 April 2026, with joining details set out in the AGM Notice. Shareholders can also request a free hard copy of the Annual Report, including the audited financial statements.

Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
-- %
Tags
current report
Rhea-AI Summary

Haleon plc reported new share-based awards granted to its Chief Executive Officer and Chief Financial Officer under its long-term incentive and bonus deferral plans. On 12 March 2026, CEO Brian McNamara received conditional awards over 1,639,855 ordinary shares under the Performance Share Plan and 173,825 shares under the Deferred Annual Bonus Plan, both at nil cost. On the same date, CFO Dawn Allen received conditional awards over 712,784 shares under the Performance Share Plan and 95,513 shares under the Deferred Annual Bonus Plan, also at nil cost. The main Performance Share Plan awards are subject to performance conditions through 31 December 2028, are aligned with Haleon’s Directors’ Remuneration Policy, and are subject to malus and clawback provisions.

Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
-- %
Tags
current report
-
Rhea-AI Summary

Haleon plc reported modestly lower 2025 revenue of £11,030m, slightly down from £11,233m in 2024, but delivered stronger profitability. Operating profit rose to £2,412m and profit after tax increased to £1,680m, lifting basic earnings per share to 18.6p from 15.8p.

Cash generation was solid, with net cash inflow from operating activities of £2,634m. The balance sheet strengthened as total liabilities fell to £16,146m and net assets grew to £16,484m. For 2025, dividends paid totalled £612m, and the Board proposes a further 4.9p final dividend.

The company highlights a focus on health and safety, with a 2025 reportable injury and illness rate of 0.14 per 100,000 hours and no fatalities. Cyber security remained a principal risk area, with a dedicated function, a CEO-led culture campaign, and no significant cyber incidents identified in 2025.

Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
-- %
Tags
annual report
-
Rhea-AI Summary

Haleon plc is starting a share buyback programme to repurchase its ordinary shares for up to an aggregate consideration of £500 million. The programme follows its 2025 preliminary full year results announcement and is aligned with its capital allocation priorities, including delivering attractive shareholder returns.

Haleon has signed an irrevocable agreement with HSBC Bank plc, which will independently decide the timing of purchases on the London Stock Exchange, CBoE Equities Europe, and Aquis, including during closed periods. The buyback begins immediately and will end no later than 19 August 2026.

Purchases before the 2026 Annual General Meeting will use the existing 2025 shareholder authority, and any later purchases will rely on authority sought at the 2026 AGM, if approved. All repurchased shares will be cancelled to reduce Haleon’s share capital, and there is no guarantee the full programme will be completed.

Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
-- %
Tags
current report
Rhea-AI Summary

Haleon plc provided an update on its total voting rights and share capital. As at 28 February 2026, the company had 8,952,353,648 issued ordinary shares of £0.01 each, with 43,969,144 held as treasury shares. This leaves 8,908,384,504 ordinary shares carrying voting rights.

The company states that this voting-rights figure should be used by shareholders and others with notification obligations as the denominator when calculating whether they must disclose interests or changes in interests under the FCA's Disclosure Guidance and Transparency Rules.

Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
-- %
Tags
current report

FAQ

How many HALEON PLC (HLNCF) SEC filings are available on StockTitan?

StockTitan tracks 54 SEC filings for HALEON PLC (HLNCF), including 10-K annual reports, 10-Q quarterly reports, 8-K current reports, and Form 4 insider trading disclosures. Each filing includes AI-generated summaries, impact scoring, and sentiment analysis.

When was the most recent SEC filing for HALEON PLC (HLNCF)?

The most recent SEC filing for HALEON PLC (HLNCF) was filed on April 1, 2026.

HLNCF Rankings

HLNCF Stock Data

44.42B
8.92B
Drug Manufacturers - Specialty & Generic
Healthcare
Link
United Kingdom
Weybridge

HLNCF RSS Feed